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Abstract. We followed parasite genotypes of 75 patients for 42 days after treatment of uncomplicated malaria with
chloroquine + sulfadoxine-pyrimethamine in Kampala, Uganda. Infections were complex (mean, 2.88 strains) and
followed three patterns: 27% of patients eliminated all strains and remained parasite-free, 48% had a long aparasitemic
interval followed by reappearance of original strains after 3–33 days (mean, 9.2 days), and 25% failed to clear original
strains and required therapy after 3–35 days (mean, 17 days). These results highlight the complexity of malaria in Africa
and have implications for efficacy trials, because missing late reappearances of strains could lead to misclassification of
outcomes.
INTRODUCTION
In sub-Saharan Africa, malaria is highly endemic, infections
are often polyclonal, and antimalarial regimens are limited by
drug resistance. Therefore, treatment is commonly followed
by either recrudescent or new infections. In this setting, it is of
interest to rigorously evaluate the dynamics of malaria infec-
tions after therapy. A number of studies have analyzed para-
site dynamics during asymptomatic plasmodial infections.1,2
Some reports noted a 48-hour periodicity in the appearance
of strains, suggesting synchronicity of polyclonal Plasmodium
falciparum infections.1–4 The complexity of infection gener-
ally remained stable over time, but specific genotypes var-
ied.2,3,5 Increasing complexity of asymptomatic infection, in-
creasing parasitemia, and the appearance of novel strains
were associated with an increasing risk of developing clinical
symptoms.6,7
Few studies have analyzed the dynamics of infection after
treatment of malaria. In patients with uncomplicated malaria
evaluated in France, parasite genotypes varied within hours
of treatment with quinine.8 In contrast, in patients with un-
complicated malaria evaluated in Sweden, genotypes at 12-
hour intervals during therapy remained remarkably con-
stant.9 These studies were comprised of patients returning to
nonendemic countries; thus, the impact of new infections on
complexity of infection could not be examined. We were in-
terested in the dynamics of malaria in Africans living in an
area of high transmission and treated with a common, albeit
sub-optimal regimen. We therefore evaluated 75 patients di-
agnosed with uncomplicated malaria in Uganda and treated
with chloroquine + sulfadoxine/pyrimethamine (CQ/SP), the
standard treatment for uncomplicated malaria in Uganda.
MATERIALS AND METHODS
Study site and population. Patients presenting to the out-
patient department of Mulago Hospital in Kampala, Uganda,
between December 2003 and August 2004 were evaluated.
Patients with a positive screening thick blood smear were
enrolled if they met the following inclusion criteria: 1) age of
at least 6 months; 2) history of fever in the last 24 hours or
tympanic temperature of at least 38.0°C; 3) P. falciparum
mixed or mono-infection with a parasite density of no more
than 400,000/L; 4) no history of serious side effects to study
medications; 5) no evidence of a concomitant febrile illness;
6) provision of informed consent; 7) ability to participate in
42-day follow-up; 8) absence of pregnancy based on history of
last menstrual period; and 9) no danger signs (prostration,
inability to drink, recent convulsion, persistent vomiting) or
evidence of severe malaria. Patients received directly ob-
served therapy with CQ/SP (Cosmoquine, Cosmos, sequential
10, 10, and 5 mg/kg daily doses; Fansidar, Roche, 25 mg/kg
sulfadoxine and 1.25 mg/kg pyrimethamine as a single dose)
and were followed for 42 days. Treatment outcomes were
classified according to 2003 World Health Organization
guidelines as early treatment failure (ETF)—danger signs,
complicated malaria, or failure to adequately respond days
0–3—late clinical failure (LCF)—danger signs, complicated
malaria, or fever and parasitemia on days 4–42 without meet-
ing criteria for ETF—late parasitological failure (LPF)—
asymptomatic parasitemia on day 42 without meeting criteria
for ETF or LCF—and adequate clinical and parasitological
response (ACPR)—absence of parasitemia on day 42 without
meeting criteria for ETF, LCF, or LPF.10 Patients classified as
ETF, LTF, or LPF were treated with quinine 10 mg/kg three
times a day for 7 days. The Institutional Review Boards of the
University of California, San Francisco and Makerere Uni-
versity approved this study. Blood was collected on filter pa-
per (Whatman no. 3) daily for the first week and thrice
weekly for 5 subsequent weeks. After the first week a medical
officer who recorded the patient’s temperature and obtained
a fingerprick blood sample performed home visits at 2- to
3-day intervals during the week. Also, patients were asked to
return to clinic once a week, where interim history, a physical
exam, and fingerprick blood samples were collected.
Molecular genotyping of parasite DNA. Parasite DNA was
extracted with chelex.11 The block 3 region of merozoite sur-
face protein-2 (msp-2) was amplified by nested polymerase
chain reaction (PCR) with primers corresponding to con-
served sequences flanking this region5 followed by primers to
amplify the IC3D7 and FC27 allelic families.12 3D7 and HB3
genomic DNA was used for positive controls. PCR products
were analyzed by electrophoresis using 2.0% Tris-Borate
EDTA agarose gels. All samples from a single patient were
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run on the same gel. If there was no amplification for any
allelic family on any day with a corresponding positive blood
smear, PCR was repeated with 2.5 times the quantity of DNA
for all samples from that patient. If no amplification was de-
tected after this second attempt, genotyping was classified as
unsuccessful. Of the patients included in this analysis, one
patient had a single sampling day with a positive microscopy
result but a negative PCR result. Gel images were digitized,
and molecular weights were assigned to bands using GelCom-
par II software (Applied Maths, Austin, TX). Each band as-
signed a molecular weight was considered an individual
strain. When comparing days, strains were considered the
same if molecular weights were within 15 bp. Treatment out-
comes were adjusted by comparing genotypes on the day of
failure with those at presentation (day 0 or day 1). Recrudes-
cences were defined as LCFs and LPFs when all strains de-
tected on the day of failure were also seen at presentation,
new infections as LCFs and LPFs when no strains present on
the day of failure were seen on presentation, and mixed out-
comes as LCFs and LPFs when the day of failure sample
contained both original and new strains. For sequencing,
PCR products were treated with ExoSAP-IT (US Biochem-
icals, Cleveland, OH) and sequenced by standard methods.
ClustalW analysis was performed using Lasergene software
(DNAStar, Madison, WI). For analysis of polymorphisms,
PCR amplification of portions of the P. falciparum dihydro-
folate reductase (dhfr) and dihydropteroate synthetase (dhps)
genes and identification of genotypes by restriction endonu-
clease digestion were performed as previously described.13,14
Statistical analysis. Statistical tests were conducted using
Stata version 8.0 (Stata Corp., College Station, TX). Com-
parisons of patient age and pre-treatment complexity of in-
fection across the three genotyping patterns were made using
a non-parametric test of trend (extension of Wilcoxon rank-
sum test). Comparisons of pre-treatment geometric mean
parasite density across the genotyping patterns were made
using analysis of variance (ANOVA).
RESULTS AND DISCUSSION
Among the 75 patients who completed the study, the mean
age was 7.8 years (range, 9 months to 37 years), and 45% of
patients were women. On day 0, the geometric mean parasite
density was 46,410 parasites/L (range, 440–281,600 para-
sites/L), and the mean complexity of infection was 2.88
(range, 1–10). The anti-malarial efficacy of CQ/SP was quite
poor. Early treatment failures were uncommon (8%), but
only 33% of patients had an adequate clinical and parasito-
logical response after 42 days of follow-up. Forty-nine percent
of patients were late clinical failures, and an additional 9%
were late parasitological failures. Clinical failures occurred
within 14 days of the onset of therapy in 30%, within 28 days
in 87%, and by day 35 in the remaining subjects. Genotyping
showed that, among late clinical and parasitological failures,
55% were caused by mixed or new infections and 45% by
recrudescence.
Frequent sampling provided numerous data points by
which to follow parasite dynamics over 42 days after treat-
ment. Gel patterns generated from msp-2 genotyping varied
among patients. We identified three distinct patterns of para-
site clearance. In pattern 1 (20 patients, 27%), parasites
present on day 0 or day 1 cleared after therapy and did not
recur through the course of follow-up (Figure 1A). All of
these patients cleared original infecting strains within 3 days
after treatment. New strains appeared in 65% of these pa-
tients but were usually cleared (77%).
In pattern 2 (36 patients, 48%), genotyping revealed a long
aparasitemic interval (defined as at least 3 days between posi-
tive PCR results; mean, 9.2 days; range: 3–35 days) followed
by reappearance of original infecting strains (Figure 1, B and
C). Among these patients, 22 also had new strains appear
during follow-up. In all cases, during intervals deemed apara-
sitemic based on PCR, parasite smears were also negative. No
periodicity in the appearance of strains was observed. To con-
firm that strains that appeared after a long interval were re-
crudescent, as suggested by msp-2 banding patterns, we se-
quenced msp-2 alleles in nine patients with monoclonal infec-
tions. All studied patients had the same (> 98% identity)
sequences, indicating that parasites commonly circulated at
levels below microscopy and PCR limits of detection for
many days before recrudescences. Previous studies of asymp-
tomatic infection have shown that introduction of new strains
is associated with increased risk of developing clinical symp-
toms.6,7 We examined the timing of appearance of new strains
in relation to time of clinical failure and found that, for the 24
patients requiring rescue therapy in this pattern, 5 (21%) had
a new strain appear one sampling frame before or on the day
of clinical failure.
In pattern 3 (19 patients, 25%), original strains were not
cleared after treatment (parasites absent at only a single time-
point, flanked by microscopy-positive time-points, were not
considered to have been cleared); the majority of patients
(N  16) required rescue therapy 3–35 days after CQ/SP
treatment (Figure 1D). Parasite density increased 1–2 days
before presentation, with recurrent fever in 11 patients
(58%). Complexity of infection increased before presentation
with fever in only five patients (26%). Of the 16 patients who
required rescue therapy in this pattern, 4 (25%) had new
strains appear one sampling frame before or on the day of
clinical failure. Therefore, the majority of failures could be
attributed to original infecting strains.
Considering all patterns over the course of follow-up, most
identified strains were those observed at the onset of the
study (Table 1). For 44 (59%) patients, baseline strains per-
sisted through follow-up. For 21 of these patients, only base-
line strains were detected. A total of 42 (56%) patients had
new strains appear during follow-up. Among these individu-
als, new strains persisted in the absence of original strains in
5 patients (12%), original and new strains persisted in 14
(33%), original strains persisted after clearance of new strains
in 9 (21%), and all strains were cleared in 14 (33%). In con-
trast to results from studies of asymptomatic infection,6,7 on-
set of recurrent malaria was mostly preceded by the presence
of original infecting strains, rather than new strains.
A comparison of baseline data between the three genotyp-
ing patterns revealed some significant differences between
the patient populations. As clearance of parasite strains di-
minished, there was a significant decrease in median age (pat-
tern 1, 10 years; pattern 2, 7 years, pattern 3, 4 years; P 
0.04), a significant increase in pre-treatment geometric mean
parasite density (pattern 1, 8,840/L; pattern 2, 27,000/L;
pattern 3, 34,560/L; P < 0.001), and a trend toward a higher
mean complexity of infection (pattern 1, 2.3; patterns 2 and 3,
3.1; P 0.18). Thus, age and parasite burden were significant
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FIGURE 1. Genotyping patterns after chloroquine/sulfadoxine-pyrimethamine therapy. At the indicated time-points, the IC3D7 and FC27
alleles of msp-2 were amplified, and products were resolved by electrophoresis. Representative results are shown for (A) a patient who cleared
all strains (pattern 1), (B and C) two patients who experienced a long aparasitemic interval followed by recrudescence of original strains (pattern
2), and (D) a patient who did not clear infection, leading to treatment failure (pattern 3). Molecular weight markers (M), a negative control (Neg),
and positive controls for the two alleles (3D7 for IC3D7 and HB3 for FC27) are indicated on each gel. Accompanying graphs show the dynamics
of infection in the same patients.
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factors in determining how well a patient cleared parasites
after treatment.
These results indicate that exposure of parasites to drug
pressure, with potential selection for resistance-mediating
mutations, is common after treatment with CQ/SP. To assess
the selection of resistant parasites, we evaluated key markers
of resistance to SP (dhfr 59, dhps 540, and dhps 437) in 21
patients who had long aparasitemic intervals followed by re-
appearance of original isolates. Of evaluated patients, four
had changes in molecular markers during the aparasitemic
interval. Two patients showed shifts from mixed to mutant
genotypes of dhfr 59, one from wild-type to mutant for dhps
437 and dhps 540 and mutant to mixed for dhfr 59, and one
from mixed to mutant for dhps 437 and dhps 540. Although
numbers for this analysis were small, the results suggest se-
lection for resistance by CQ/SP.
In summary, after therapy with a standard, albeit sub-
optimal, regimen for uncomplicated malaria, the dynamics of
infection and interplay between original and new strains were
complex. Perhaps of greatest interest, a surprisingly large
number of patients (48%) had long breaks without parasit-
emia detectable by microscopy or PCR followed by the reap-
pearance of original infecting strains. These patients had
lower mean age and higher pre-treatment parasite density
than patients who were able to clear all original parasites.
This observation indicates that, in malaria-immune individu-
als, parasites can persist in low numbers for extended periods
of time, followed by multiplication to levels that cause recur-
rent illness. This result has important implications for drug
efficacy studies. Follow-up that is not sufficiently long or that
does not assess multiple time-points might miss late recrudes-
cent infections, leading to misclassification of outcomes. It is
likely that the use of CQ/SP, a drug that has a long half-life
and intermediate antimalarial activity in Uganda,15 contrib-
uted to the high frequency of aparasitemic intervals after
therapy. It will be of interest to study parasite dynamics after
treatment with regimens with different pharmacokinetic and
drug resistance profiles.
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TABLE 1
Appearance of original and new strains through follow-up
Level of strain clearance N (%)
All strains cleared 14 (18.7)
All strains persist 14 (18.7)
Original strains cleared, no new strains appear 12 (16.0)
Original strains cleared, new strains persist 5 (6.7)
Original strains persist, no new strains appear 21 (28.0)
Original strains persist, new strains cleared 9 (12.0)
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